Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | Can anthracyclines be omitted in TNBC?

The omission of anthracyclines was a highly debated topic at the St. Gallen Consensus Session 2021. Lisa Carey, MD, FASCO, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, talks on the necessity of anthracyclines in triple negative breast cancer (TNBC). While the toxicity profile of these drugs makes their omission appealing, evidence continues to support their use in TNBC. This interview took place during the 17th St. Gallen International Breast Cancer Conference.


Prof. Carey reports institutional financial interests with the following commercial entities: Novartis, G1 Therapeutics, Genetech/Roche, Lilly, Innocrin, Seattle Genetics, Merck, Immunomedics.